Pulmonary administration of immunoglobulin single variable domains and constructs thereof

Patent metadata

Field	Value
Publication number	US-9725522-B2
Application number	US-201615063961-A
Country	US
Kind code	B2
Filing date	Mar 8, 2016
Priority date	Nov 8, 2002
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules.
In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.

First claim

What is claimed is:

1. An inhaler device for use in delivery of a construct that consists essentially of one or more Nanobodies to the systemic circulation by passive absorption comprising an effective amount of a construct that consists essentially of one or more Nanobodies, wherein said construct is passively absorbed into the systemic circulation from the pulmonary tissue and specifically binds at least one druggable antigen expressed in a mammal but expressed outside the pulmonary tissue of said mammal.

2. The inhaler device of claim 1 , wherein the inhaler device is an inhaler for liquids.

3. The inhaler device of claim 2 , wherein the inhaler for liquids is a nebulizer or a metered dose inhaler.

4. The inhaler device of claim 3 , wherein the nebulizer is an air-jet nebulizer, ultrasonic nebulizer or vibrating mesh nebulizer.

5. The inhaler device of claim 1 , wherein the inhaler device is a dry powder inhaler.

6. The inhaler device of claim 1 , wherein said construct is selected from the group consisting of a Nanobody, a construct comprising or essentially consisting of two Nanobodies directed against the same or different antigens, optionally connected by a linker, and a construct comprising or essentially consisting of three Nanobodies directed against the same or different antigens, optionally connected by a linker.

7. The inhaler device of claim 1 , wherein the one or more Nanobodies is a VHH or a humanized VHH.

Assignees

• Ablynx Nv

Inventors

• Bouche Marie-Paule Lucienne Armanda
• Vanlandschoot Peter
• Sablon Erwin
• Depla Erik
• De Buck Stefan
• Saelens Xavier
• Schepens Bert
• Silence Karen
• Vaeck Mark
• Van Bergen En Henegouwen Paul M P
• De Haard Hans

Classifications

• C07K16/11

  Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV] · CPC title

• C07K16/468

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• A61M15/0065

  Inhalators with dosage or measuring devices (A61M15/0028 takes precedence; dosage devices incorporated in aerosol cans B65D83/52) · CPC title

• A61M11/005

  using ultrasonics (spraying or atomising liquids using ultrasonic vibrations in general B05B17/06) · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title